Welcome, Guest. Please login or register.
August 09, 2020, 01:14:34 am

Login with username, password and session length

  • Total Posts: 703
  • Total Topics: 252
  • Online Today: 11
  • Online Ever: 334
  • (July 01, 2012, 10:57:46 pm)
Users Online
Users: 0
Guests: 9
Total: 9


Welcome to the Real Health Forums. Share your stories and thoughts on the many health challenges facing us today. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Real Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA OKs New Heart Disease Drug That Can Cut Death Risk Substantially  (Read 6591 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 65
The U.S. Food and Drug Administration (FDA) recently approved a new cardiovascular disease drug shown to reduce the number of patients needing hospitalization for and dying of heart failure, The New York Times reports.

The drug is called Entresto (known during development as LCZ696). Novartis makes the  pill, which combines two drugs, valsartan and sacubatril. Patients must take the drug twice each day.

Anticipation for the drug has been mounting since early 2014, when results of a large clinical trial found patients who took the drug enjoyed a massive decrease in the risk of death as well as heart-related hospitalizations when compared to patients taking older heart failure meds, such as angiotensin-converting enzyme (ACE) inhibitors and similar angiotensin II receptor blockers.



© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.